$47.3 Million is the total value of Atlas Venture Associates IX, LLC's 6 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTLA | INTELLIA THERAPEUTICS INC | $19,756,000 | -16.6% | 1,615,321 | 0.0% | 41.77% | +1.2% | |
| SPRO | SPERO THERAPEUTICS INC | $11,126,000 | -16.0% | 1,376,968 | 0.0% | 23.53% | +1.9% | |
| SURF | SURFACE ONCOLOGY INC | $8,687,000 | -0.5% | 4,645,453 | 0.0% | 18.37% | +20.7% | |
| SYBX | SYNLOGIC INC | $4,561,000 | -33.3% | 2,651,963 | 0.0% | 9.64% | -19.1% | |
| SNAP | SNAP INCcl a | $1,785,000 | -27.2% | 150,160 | 0.0% | 3.77% | -11.7% | |
| UMRX | UNUM THERAPEUTICS INC | $1,378,000 | -43.1% | 3,361,535 | 0.0% | 2.91% | -30.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTELLIA THERAPEUTICS INC | 28 | Q3 2023 | 100.0% |
| SNAP INC | 26 | Q3 2023 | 11.4% |
| SPERO THERAPEUTICS INC | 24 | Q3 2023 | 24.0% |
| SYNLOGIC INC | 24 | Q2 2023 | 35.6% |
| SURFACE ONCOLOGY INC | 21 | Q2 2023 | 33.3% |
| SKILLZ INC | 12 | Q3 2023 | 87.5% |
| UNUM THERAPEUTICS INC | 11 | Q3 2020 | 28.2% |
| COGENT BIOSCIENCES INC | 7 | Q2 2022 | 9.6% |
| CARBON BLACK INC | 6 | Q3 2019 | 7.8% |
| COHERUS BIOSCIENCES INC | 1 | Q3 2023 | 18.1% |
View Atlas Venture Associates IX, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-08 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-01-27 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-08-11 |
View Atlas Venture Associates IX, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.